NVS Novartis (NVS) Insider Trading, Ownership & Congress Trades
What the filings say about NVS
Novartis insider trades (Form 4)
No insider purchases or sales are on record for NOVARTIS AG in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.
no insider purchases or sales on record
Watch NVS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns NVS: institutional holders (13F)
Congress trades in NVS
Activist and 5% holders (13D/13G)
NVS planned insider sales (Form 144)
NVS mutual fund holders (N-PORT)
NVS financials
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Gross profit | $43.0B | $38.9B | $34.2B | $31.9B |
| Net income | $14.0B | $11.9B | $14.9B | $7.0B |
NVS Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NVS filings, in plain words
Have members of Congress traded NVS?
Yes. In the year to 2026-10-27, 1 House member disclosed buying NVS and 2 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-27.
Read the full summary
In the year to 2026-10-27, 1 member of Congress disclosed buying NVS and 2 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-27. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

